News for Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Inc (ALNY), a leader in RNAi therapeutics, announced the retirement of Dr. Phillip A. Sharp from its Board of Directors, effective May 8

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D.

Strengths: Innovative AOC platform and robust pipeline with potential for significant market impact.Weaknesses: Lack of commercialization experience and high R

Bitcoin breaks below $90,000 as crypto selloff deepens. Apple, Indonesia reportedly agree on terms to end iPhone 16 ban. Drug compounders sue FDA over semaglutide status: report.

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Discover Alnylam's strong 2024 performance and 2025 growth potential driven by AMVUTTRA expansion.

Start Time: 08:30 January 1, 0000 9:28 AM ETAlnylam Pharmaceuticals, Inc.

The following slide deck was published by Alnylam Pharmaceuticals, Inc.

Alnylam (ALNY) delivered earnings and revenue surprises of 128.57% and 4.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is how Alnylam Pharmaceuticals (ALNY) and Medpace (MEDP) have performed compared to their sector so far this year.

Edinburgh Worldwide IT reports annual growth, appoints new director

Alnylam Pharmaceuticals Inc (ALNY), a leader in RNAi therapeutics, has released its preliminary financial results for the fourth quarter and full year 2024, sho

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Alnylam Pharmaceuticals Inc (ALNY), a leader in RNAi therapeutics, announced that its management will present a company overview and participate in a Q&A sessio

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overvi

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference